Aktis Oncology (AKTS) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Aktis Oncology (NASDAQ: AKTS) recently:

• 2/3/2026 – Aktis Oncology is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $30.00 price target on the stock.
• 2/3/2026 – Aktis Oncology is now covered by analysts at Bank of America Corporation. They set a “buy” rating and a $34.00 price target on the stock.
• 2/3/2026 – Aktis Oncology is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $31.00 price target on the stock.
• 2/3/2026 – Aktis Oncology is now covered by analysts at TD Cowen. They set a “buy” rating on the stock.
• 1/17/2026 – Aktis Oncology was upgraded by analysts at Wall Street Zen to a “hold” rating.

Insider Activity

In other Aktis Oncology news, Director Helen Susan Kim acquired 835,000 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was bought at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the purchase, the director owned 5,671,825 shares in the company, valued at $102,092,850. This represents a 17.26% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Ansbert Gadicke bought 1,112,777 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the transaction, the insider owned 10,260,064 shares in the company, valued at $184,681,152. This represents a 12.17% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 6,117,776 shares of company stock valued at $110,119,968. 3.30% of the stock is owned by insiders.

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.